A Global Threat Accelerates
A new World Health Organization (WHO) report, The Global Antibiotic Resistance Surveillance Report 2025, delivers a stark warning: the rise of antimicrobial resistance (AMR) is outpacing our ability to combat it. Between 2018 and 2023, resistance increased in over 40% of the pathogen-antibiotic combinations monitored, with an average annual rise of 5-15%.
The burden is not shared equally. The report estimates that antibiotic resistance is highest in the WHO South-East Asian and Eastern Mediterranean Regions, where a staggering 1 in 3 reported infections were resistant. This escalating crisis threatens to undermine modern medicine, making common infections once again life-threatening and jeopardizing the success of surgeries, chemotherapy, and other critical procedures.
The Diagnostic Gap in the AMR Fight
The WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, emphasized that combating AMR requires strengthening surveillance and ensuring access to the right medicines and diagnostics. A critical bottleneck in this fight is the time it takes to accurately identify resistant pathogens. Traditional methods can take days, forcing clinicians to prescribe broad-spectrum antibiotics empirically—a practice that fuels the very cycle of resistance.
This is where cutting-edge diagnostics are poised to change the game. By providing rapid, precise identification of resistance mechanisms, they empower healthcare providers to make informed, life-saving decisions immediately.
Macro & Micro-Test’s Solutions: Precision Diagnostics to Combat the AMR Crisis
In direct response to the challenges outlined by the WHO, we offer two integrated diagnostic solutions designed to deliver the speed, accuracy, and flexibility needed to safeguard patients and protect healthcare systems.
Solution 1: CE-Certified Rapid Carbapenemase Detection Kit
-Unmatched Speed & Precision: This groundbreaking instrument-free kit detects the five key carbapenemase genes (KPC, NDM, OXA-48, VIM, IMP)—covering >95% of known clinical variants—in just 15 minutes. With a sensitivity of >95%, it provides highly reliable results at the point of need, turning a waiting period of days into a moment of decisive action.
-Guides Immediate Targeted Therapy: The kit transforms clinical management by delivering actionable data immediately. This enables clinicians to initiate the most effective antibiotic therapy right away, dramatically improving outcomes for high-risk patients in ICU, oncology, and surgical wards.
-Protects Healthcare Systems: It serves as an essential tool for infection control and antimicrobial stewardship programs. Its rapidity is critical for preventing outbreaks in high-risk settings, helping to reduce hospital stays and associated costs, thereby protecting institutional resources.
Solution 2: The Integrated Power of AIO800 + Molecular CRE Kit
Sample-to-Answer Molecular POCT provides the complete and accurate solution.
-Comprehensive Multiplex Detection: This solution identifies six major carbapenemase genes (KPC, NDM, OXA-48, OXA-23, VIM, IMP) in a single assay. This extensive coverage streamlines workflows, reduces the need for multiple tests, and significantly cuts diagnostic costs.
- High Sensitivity & Specificity: Engineered for exceptional accuracy, the kit detects as low as 1,000 CFU/mL with zero cross-reactivity, ensuring reliable diagnostics even in complex, polymicrobial specimens.
-Maximum Platform Flexibility: Designed for broad adoption, the kit is compatible with both the fully automated, high-throughput AIO800 system and conventional PCR instruments.
The AIO800 system redefines efficiency with its fully integrated design, providing results in as little as 76 minutes while incorporating an 11-layer safety system to minimize contamination risks.
Turning the Tide with Timely Intelligence
The latest WHO data makes it clear that AMR is not a future threat but a present and growing danger. The path forward requires a multifaceted approach where advanced diagnostics play a pivotal role. Our solutions provide the “timely intelligence” needed to stay ahead of resistant pathogens, enabling targeted therapy, containing outbreaks, and upholding global antibiotic stewardship standards.
Contact to learn more: marketing@mmtest.com
Post time: Jan-19-2026